Gossamer Bio to Participate in Upcoming Investor Conferences
SAN DIEGO--( BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in December.
Piper Sandler 37 th Annual Healthcare Conference
Date / Time:
December 2 nd, at 9:00 AM ET
Format:
Presentation & 1x1’s
Location:
New York, NY
Oppenheimer Movers in Rare Disease Summit
Date / Time:
December 11 th, at 9:00 AM ET
Format:
Panel & 1x1’s
Location:
New York, NY
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.